TG THERAPEUTICS, INC. Form 8-K March 06, 2017

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

## FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 6, 2017

TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware 001-32639 (State or Other Jurisdiction (Commission File Number) 36-3898269 (IRS Employer Identification No.)

2 Gansevoort Street, 9th Floor New York, New York 10014 (Address of Principal Executive Offices)

(212) 554-4484 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act. Soliciting material pursuant to Rule 14a-12 under the Exchange Act. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Item 8.01. Other Events.

On March 6, 2017 TG Therapeutics, Inc. issued a press release in which it reported topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk chronic lymphocytic leukemia (CLL). A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated March 6, 2017.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc. (Registrant)

Date: March 6, 2017

By: /s/ Sean A. Power Sean A. Power Chief Financial Officer

## INDEX TO EXHIBITS

Exhibit Number Description

99.1. Press Release, dated March 6, 2017